What is the difference between Cassipa and Suboxone sublingual film?

Cassipa sublingual films contain 16mg buprenorphine and 4mg naloxone in each film. Suboxone sublingual films contain buprenorphine and naloxone at a lower dosage.

According to the FDA, the Cassipa (buprenorphine and naloxone) brand sublingual film has been discontinued.

In September 2018, the U.S. Food and Drug Administration (FDA) approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance (longer-term) treatment of opioid dependence.

Cassipa provides a new dosage strength of sublingual film:

• buprenorphine 16 mg / naloxone 4 mg.

Buprenorphine is a a partial opioid agonist and naloxone blocks the effects of opioid medication that can lead to opioid abuse. Both buprenorphine and naloxone have been approved previously for this purpose.

Suboxone sublingual, another brand name of buprenorphine and naloxone sublingual film, is available in the following film strengths:

• buprenorphine 2 mg / naloxone 0.5 mg
• buprenorphine 4 mg / naloxone 1 mg
• buprenorphine 8 mg / naloxone 2 mg
• buprenorphine 12 mg / naloxone 3 mg.

Side effects of these medications may include:

• oral numbness
• burning mouth
• inflammation of the mouth's mucous membrane
• headache
• nausea and vomiting
• excessive sweating
• constipation.